Skip to content

Computerized Anxiety Treatment for Suicide

Suicide Risk Prevention Among Patients With Anxiety Psychopathology

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01990131
Acronym
CATS
Enrollment
74
Registered
2013-11-21
Start date
2013-10-31
Completion date
2016-07-31
Last updated
2016-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Suicide

Keywords

computerized intervention, cognitive bias modification, anxiety, suicide

Brief summary

The purpose of this study is to test the effectiveness and usability of multiple computer-based treatments for mood and anxiety relevant risk factors. The target of the treatment is related to cognitive stress, which has been shown to be associated with a variety of negative mental health outcomes such as Post-Traumatic Stress Disorder, suicidal ideation, and substance use disorders.

Detailed description

CATS is a newly developed computerized treatment targeting specific risk factors associated with anxiety symptoms and suicidal thoughts. Individuals will be asked to complete four appointments, where they will complete various self-report questionnaires as well as a newly developed computerized treatment targeting risk factors associated with anxiety.

Interventions

Sponsors

Florida State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Meet diagnostic criteria for a primary Axis 1 anxiety disorder or meet diagnostic criteria for a unipolar mood disorder along with an Axis 1 anxiety disorder. * Show evidence of current suicidal ideation (BSS above 6. * Show elevated AS indicated by scoring at or above the community sample mean on the ASI-Cog (above 9.

Exclusion criteria

* No significant medical illness (e.g. sig cardiovascular disease, epilepsy, stroke). * Current or past psychotic-spectrum disorders or uncontrolled bipolar disorder * No current substance dependence * Must be an English speaker. * Must be 18 years or older. * Must have normal or corrected vision * Cannot begin treatment/therapy within 1 month of baseline. * Cannot begin a new medication within 3 months of baseline.

Design outcomes

Primary

MeasureTime frameDescription
Anxiety Sensitivity Index-3 (ASI-3)Month 4 follow-upThe ASI-3 is an 18-item self-report measure of anxiety sensitivity (AS). This scale was developed to provide a more stable measure of the three most widely recognized AS subfactors (cognitive, social and physical concerns) than the original ASI provides. Each subfactor is represented by six items. The measure has shown good psychometric properties.

Secondary

MeasureTime frameDescription
Beck Suicide Scale (BSS)Month 4 follow-upThe BSS is a 21-item widely used self-report measure assessing a broad spectrum of behaviors and attitudes related to suicide risk, including suicidal ideation and past suicide attempts. It has demonstrated strong reliability and validity.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026